Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR lossHuayang Liu, E. Robert McDonald, Lauren K. Brodeur et al.|Nature Medicine|2018Cited by 369
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412Joseph D. Growney, D. Gary Gilliland|Blood|2005Cited by 250